Cannabis Rescheduling Opens the Door to Federal Tax Relief and R&D Tax Credits

A recent shift in federal policy materially changes how certain cannabis businesses should evaluate their Research and Development (R&D) Tax Credit position. On April 22, 2026, the Drug Enforcement Administration (DEA) issued a final order rescheduling specific cannabis products from Schedule I to Schedule III under the Controlled Substances Act. This change applies primarily to FDA approved products and those sold under qualifying state issued medical licenses and has direct implications for federal R&D tax credit eligibility beginning in 2026.

Historically, cannabis businesses operated under one of the most restrictive tax regimes in the Internal Revenue Code. Section 280E disallowed deductions for ordinary and necessary business expenses for companies engaged in Schedule I or II substances. In practice, this also limited the ability to fully benefit from R&D-related tax provisions. Even where qualifying research activities existed, the impact of the R&D tax credit was often muted by the 280E constraints on the treatment of related expenses.

The DEA’s rescheduling removes that constraint for eligible medical cannabis businesses. Once classified as Schedule III, Section 280E no longer applies, allowing businesses to deduct operating expenses and, importantly, evaluate R&D tax credits as a meaningful federal tax benefit. This is a structural shift. For the first time, many cannabis operators can treat the R&D credit as a primary tax planning tool rather than a secondary consideration.

This change elevates the importance of identifying qualified research activities under Section 41. Many cannabis companies are already performing development work that may satisfy the four part test, but have not historically approached these efforts through a tax lens. With rescheduling, those same activities can translate into defensible, recurring federal tax credits when properly identified and documented.

Common cannabis industry activities that may qualify for the R&D tax credit include:

Product formulation and refinement: Development of new strains, cannabinoid ratios, or delivery formats to improve efficacy, stability, or user experience.
Extraction and processing methods: Designing and optimizing extraction techniques (CO₂, ethanol, solventless) to improve yield, purity, and consistency.
Cultivation and grow optimization: Experimentation with lighting, nutrients, genetics, and environmental controls to increase yield or product quality.
Process engineering and scale-up: Transitioning lab scale processes to commercial production, including equipment design, throughput optimization, and waste reduction.
Product stability and shelf-life testing: Evaluating degradation, packaging impacts, and environmental conditions to ensure consistency over time.
Infusion and delivery technologies: Developing edibles, beverages, tinctures, and other delivery systems with consistent dosing and bioavailability.
Quality control and testing protocols: Designing analytical methods for potency, contaminants, and consistency across batches.

These activities often involve technical uncertainty, iterative testing, and evaluation of alternatives, the core elements the IRS evaluates under Section 41. When tied to specific business components and supported with contemporaneous documentation, they can form the basis of a defensible R&D tax credit position.

Many states have already decoupled from Section 280E and offer their own R&D tax credit incentives. The federal change brings closer alignment and increases the total value of credits available. Companies that have evaluated R&D tax credits at the state level should revisit those positions under the new federal framework.

The impact is not uniform. The DEA’s order is limited to medical cannabis and FDA approved products. Recreational businesses remain subject to Section 280E. Dual licensed operators will need to evaluate activities at the business component level and may need to segregate research activities and costs between qualifying and non qualifying operations.

Additional guidance from Treasury and the IRS is expected, but the direction is clear. For eligible businesses, 2026 is the first year in which the R&D tax credit becomes a viable federal tax-planning opportunity. Companies that approach this proactively by identifying qualifying work, aligning costs, and implementing disciplined documentation will be positioned to generate meaningful and sustainable tax benefits.

Withum’s R&D Tax Credit Study Approach

Withum maintains a dedicated team of R&D tax credit specialists serving companies across all industries. Our approach is designed to help businesses identify opportunities, maximize federal and state credits, and maintain taxing authority-ready documentation to support, defend, and sustain credits year after year.

We take a fresh look at your development processes, data collection methods, and documentation practices to ensure your R&D tax credit position is accurate, defensible, and optimized.

Complimentary R&D Tax Credit Assessment

Withum offers a no-obligation complimentary R&D tax credit assessment, beginning with a brief 30-minute discussion. This conversation is designed to quickly determine whether an R&D tax credit opportunity exists and how Withum can assist in calculating, documenting, and supporting your credit through our innovative R&D tax credit studies.